<DOC>
	<DOCNO>NCT00772798</DOCNO>
	<brief_summary>TITLE : A Phase II non-comparative study paclitaxel plus carboplatin combination Vorinostat patient advance , recurrent epithelial ovarian cancer . INDICATION : Second-line treatment patient recurrent platinum-sensitive epithelial ovarian cancer . RATIONALE : Recurrent epithelial ovarian cancer today incurable disease . The current standard care consist systemic chemotherapy use either carboplatin plus paclitaxel ( platinum-sensitive patient ) single agent chemotherapy agent like liposomal doxorubicin , topotecan , weekly paclitaxel gemcitabine ( platinum non-sensitive patient ) . The outcome patient advanced ovarian cancer nevertheless remain poor.Preclinical evidence suggest vorinostat , potent histone deacetylase ( HDAC ) inhibitor , may potentiate antitumor activity paclitaxel and/or carboplatin . The study ass whether addition vorinostat paclitaxel plus carboplatin manageable induces reasonable response rate patient advanced recurrent , platinum-sensitive ovarian cancer . Biomarkers collect primary tumor biopsy start treatment vorinostat . DESIGN : Phase II , single-center study . All eligible patient treat intravenous paclitaxel plus carboplatin plus oral vorinostat . Patients treat maximum 6 cycle disease progression , unacceptable toxicity withdrawal consent . Clinical endpoint include adverse experience , progression-free survival ( PFS ) response rate ( RR ) . SAMPLE : Patients must histologically confirm diagnosis epithelial ovarian cancer , cancer Fallopian tube primary peritoneal adenocarcinoma . All patient receive first-line therapy carboplatin plus paclitaxel . Patients platinum sensitive , defined recurrence progression ovarian cancer , cancer Fallopian tube primary peritoneal adenocarcinoma 6 month later end first-line chemotherapy . Patients enrol study must acceptable performance status acceptable renal hepatic function , free serious intercurrent illness could impair ability receive protocol therapy . The study include 55 assessable patient , 20 provide biomarkers . It estimate inclusion period last approximately 24 month . DOSAGE/DOSAGE FORM , ROUTE , AND DOSE REGIMEN Eligible patient treat paclitaxel ( 175 mg/m2 ) carboplatin AUC5 administer intravenous infusion ( IV ) day 1 treatment cycle . In addition , eligible patient receive treatment oral vorinostat ( 400 mg ) administer daily mouth food day -4 10 Cycle 1 ( 25-day treatment cycle ) day 1 14 subsequent 21-day treatment cycle . Patients receive antiemetic therapy accord institutional guideline well premedication dexamethasone , antihistamine ( H1-receptor antagonist H2-receptor antagonist ) prevention side effect paclitaxel .</brief_summary>
	<brief_title>A Phase I/II Study Paclitaxel Plus Carboplatin Plus Vorinostat Recurrent Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histological verify epithelial carcinoma derive ovarian , peritoneum uterine tube 2 . Women ≥18 year old . 3 . ECOG performance status ≤2 . 4 . Expected duration life &gt; 3 month . 5 . Previous treatment regimen contain platinum paclitaxel . 6 . Platinum paclitaxel sensitive tumor , define minimum 6 month cessation treatment disease progression . 7 . Measurable assessable lesion.Patients increase CA125 sign recurrence also eligible . 8 . Normal organ function define follow value : Absolute neutrophil count ( ANC ) ≥1,500/µL Platelets ≥100,000/µL Hemoglobin ≥9.0g/dL &gt; 5.7 mmol/L CA125 035 Glomerular filtration rate ( GFR ) measure use CrEDTA clearance GFR ≥50 mL/minute ( correct body surface area ) Serum Total bilirubin ≤1.5 time ULN AST ( SGOT ) ALT ( SGPT ) ≤2.5 time ULN Alkaline phosphatase ≤5.0 time ULN Prothrombin time ( PT ) ≤1.2 time ULN unless patient receive therapeutic anticoagulation . Partial thromboplastin time ( PTT ) ≤1.2 time ULN unless patient receive therapeutic anticoagulation . 9 . Signed informed consent inclusion . 10 . Prepared appear plan followup visit capable handle toxicity . 1 . Patients treat experimental drug within last 4 week inclusion , patient receive concomitant anticancer treatment . 2 . Patients active infection , receive intravenous antibacterial antifungal medicine within last 2 week inclusion . 3 . Patients previously treat HDAC inhibitor . Patients , treat Valproate convulsion include , however treatment take place &gt; 30 day inclusion . 4 . Patients treat steroid , stabilized firm dose equivalent maximum 10 mg prednisolone per day last 4 week inclusion . 5 . Previous treatment firstline chemotherapy . 6 . Progression treatment firstline chemotherapy contain platin/paclitaxel disease progression le 6 month treatment cessation . 7 . Concomitant serious and/or noncontrollable medical condition noncontrollable infection ( include HIV infected patient ) , hypertension , ischemic heart disease , myocardial infarction within last 6 month , congestive heart failure . 8 . Previous treatment , concomitant malignant disease within last 5 year , except curative treat carcinoma situ cervical cancer basal cell carcinoma . 9 . Previous severe allergic reaction connection carboplatin , paclitaxel agent within histone deacetylase inhibitor group . 10 . Women childbearing age . Women must undergo surgical removal ovary postmenopausal menstruation previous year . 11 . Peripheral neuropathy ≥ grade 2 , unless due medical condition . 12 . Patients history severe hyper sensitive reaction regard product contain Cremophor EL ( cyclosporine Kvitamin ) and/or patient know hypersensitivity towards agent chemically connect paclitaxel , carboplatin vorinostat . 13 . Patients known cerebral metastasis clinical sign cerebral metastasis .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>vorinostat</keyword>
</DOC>